Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer - 101967

Spotlight
Video

Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer

Loading........
Description: Theodore S. Hong, MD of Massachusetts General Hospital discusses the Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer at ASCO GI 2017
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/26/17
Added : 2 years ago
Category : Pancreatic Cancer